NEW YORK — LGC Clinical Diagnostics said on Monday that it has acquired Kova International, a maker of in vitro urinalysis and toxicology quality control products for clinical laboratories.
Financial and other terms of the transaction were not disclosed.
Kova operates two facilities: one in Garden Grove, California, that focuses on urinalysis quality controls and one in Edgewood, New York, that focuses on toxicology quality controls. The products are used in hospitals, employee wellness programs, forensic testing and medical device manufacturers production, and quality assurance programs.
According to Milford, Massachusetts-based LGC, the acquisition will expand its presence in the clinical quality control space.
A little over a year ago, LGC acquired next-generation sequencing genotyping company Rapid Genomics.